{"Clinical Trial ID": "NCT03045653", "Intervention": ["INTERVENTION 1:", "Treatment arms", "- receiving tamoxifen 100 mg/day"], "Eligibility": ["Incorporation criteria:", "ECOG 0-1 with no deterioration in the previous 2 weeks Minimum life expectancy 3 months Histological confirmation of breast cancer with high hormone content (IHC:ER 60% and PR 60%) on primary tumour at diagnosis/metastasis biopsy Histological confirmation of negative breast cancer HER2 on primary tumour at diagnosis/biopsy of metastasis Disease-free time of patients relapsed is greater than 12 months Once received a standard and advanced hormonal treatment Clinical or histological confirmation of a metastatic or locally advanced disease that cannot lend itself to curative surgical resection At least one objective assessment according to the RECIST cretion or non-measurable disease but only bone metastasis Adequate function of bone marrow and organs Progressive disease while receiving endocrine treatment for locally advanced or metastatic disease B.C. or relapse with metastatic disease while receiving endocrine treatment Radiological or objective clinical evidence of reccurrence or progression on or after the last systemic treatment", "4 previous endocrine treatment lines for ABC", "3 lines of cytotoxic chemotherapy for ABC Suitable for additional endocrine treatment Availability of archival tumour sample or fresh biopsy Informed consent Normal function of organ", "- Exclusion criteria:", "- Last dose chemotherapy, targeted immunotherapy, biological treatment or tumour embolism <21 days prior to study treatment Last dose of palliative radiotherapy <7 days prior to study treatment Rapidly progressive visceral disease not suitable for further endocrine treatment Epinal cord compression or brain metastases/mining less than one asymptomatic dose, treated and stable and not requiring steroids for 4 weeks.", "\u25cf Major surgery (excluding vascular access placement) within 4 weeks prior to study treatment Evidence of serious or uncontrolled systemic diseases, including uncontrolled hypertension, active haemorrhagic diathesis or active infection including hepatitis B, hepatitis C and HIV With the exception of alopecia, any unsolved toxicity from prior treatment higher than the first year of the CTCAE study prior to high ALP treatment in the absence of bone metastases Evidence of dementia, altered mental condition or any psychiatric condition that would preclude understanding or informed consent Participation in another study with an experimental product in the last 30 days Incapacity or unwillingness to comply with study procedures, including inability to take regular oral drugs"], "Results": ["Performance measures:", "- Progression-free survival (PFS)", "[Unspecified]", "Time limit: 36 months", "Results 1:", "Title of arm/group: Treatment arm", "Description of the arm/group: receiving tamoxifen 100 mg/d", "Total number of participants analysed: 30", "Median (95% confidence interval)", "Unit of measure: months 5 (2.6 to 7.3)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/30 (0.00 per cent)"]}